KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to $702.0 million.

  • Halozyme Therapeutics' Cash & Current Investments rose 535.14% to $702.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $702.0 million, marking a year-over-year increase of 535.14%. This contributed to the annual value of $596.1 million for FY2024, which is 7740.3% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Cash & Current Investments stood at $702.0 million for Q3 2025, which was up 535.14% from $548.2 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Cash & Current Investments registered a high of $815.9 million during Q3 2021, and its lowest value of $209.4 million during Q2 2022.
  • Moreover, its 5-year median value for Cash & Current Investments was $548.2 million (2025), whereas its average is $547.2 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first soared by 13533.48% in 2021, then tumbled by 7228.15% in 2022.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Cash & Current Investments stood at $740.9 million in 2021, then crashed by 51.03% to $362.8 million in 2022, then dropped by 7.39% to $336.0 million in 2023, then surged by 77.4% to $596.1 million in 2024, then rose by 17.76% to $702.0 million in 2025.
  • Its Cash & Current Investments stands at $702.0 million for Q3 2025, versus $548.2 million for Q2 2025 and $747.9 million for Q1 2025.